AMEX:CLDI (USA)
Â
Ordinary Shares
$
0.13
-0.0082 (-5.82%)
10:08 PM EST
Business Description
Calidi Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US3207034089
Share Class Description:
CLDI: Ordinary SharesTotal Employee Number:
29Description
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.94 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.46 | |||||
Debt-to-EBITDA | -0.13 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 63 | |||||
3-Year EPS without NRI Growth Rate | 57.7 | |||||
3-Year FCF Growth Rate | 52.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.32 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.08 | |||||
9-Day RSI | 32.45 | |||||
14-Day RSI | 35.26 | |||||
3-1 Month Momentum % | -45.44 | |||||
6-1 Month Momentum % | -86.04 | |||||
12-1 Month Momentum % | -98.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.92 | |||||
Quick Ratio | 1.92 | |||||
Cash Ratio | 1.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -189 | |||||
Shareholder Yield % | -296.82 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -391.25 | |||||
ROA % | -167.23 | |||||
ROIC % | -350.5 | |||||
3-Year ROIIC % | -8.89 | |||||
ROC (Joel Greenblatt) % | -670.11 | |||||
ROCE % | -285.38 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.32 | |||||
Price-to-Tangible-Book | 0.32 | |||||
EV-to-EBIT | 0.1 | |||||
EV-to-Forward-EBIT | -0.83 | |||||
EV-to-EBITDA | 0.11 | |||||
EV-to-FCF | 0.1 | |||||
| Price-to-Net-Current-Asset-Value | 0.58 | |||||
| Price-to-Net-Cash | 0.78 | |||||
Earnings Yield (Greenblatt) % | 1000 | |||||
FCF Yield % | -717.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:CLDI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Calidi Biotherapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.192 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 201.68 | ||
| 14-Day RSI | 35.26 | ||
| 14-Day ATR ($) | 0.014987 | ||
| 20-Day SMA ($) | 0.153955 | ||
| 12-1 Month Momentum % | -98.32 | ||
| 52-Week Range ($) | 0.1201 - 10.92 | ||
| Shares Outstanding (Mil) | 19.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Calidi Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Calidi Biotherapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 122 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 24 days | ||
| General meeting for 2026 | 2026-06-12 10:00 | 0.17 (+0.90%) | ||
| RedChip Investor Webinar with Calidi Biotherapeutics | 2026-06-09 16:15 | 0.18 (+2.34%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.20 (+6.78%) | ||
| RedChip’s upcoming virtual investor conference | 2026-04-16 13:00 | 0.27 (-0.51%) | ||
| Annual report for 2025 | 2026-03-27 | 0.28 (-2.88%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-27 | 0.28 (-2.88%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 1.51 (-1.31%) | ||
| Second quarter earnings results for 2025 | 2025-08-08 | 5.76 (-1.37%) |
Show
Entries
Calidi Biotherapeutics Inc Frequently Asked Questions
What is Calidi Biotherapeutics Inc(CLDI)'s stock price today?
The current price of CLDI is $0.13. The 52 week high of CLDI is $10.92 and 52 week low is $0.12.
When is next earnings date of Calidi Biotherapeutics Inc(CLDI)?
The next earnings date of Calidi Biotherapeutics Inc(CLDI) is 2026-08-07 Est..
Does Calidi Biotherapeutics Inc(CLDI) pay dividends? If so, how much?
Calidi Biotherapeutics Inc(CLDI) does not pay dividend.
Guru Commentaries on AMEX:CLDI
No articles.
Press Release
Articles on Calidi Biotherapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers